A new designer opioid from the orphine class has turned up in fentanyl samples in Toronto, the sixth new substance found in the city’s fentanyl supply so far this year, Toronto’s Drug Checking Service said, The Canadian Press reported Thursday.
The drug was first identified in four fentanyl samples collected in October. It is so new it has no generic name yet, and its strength and effects are unknown because there is next to no research on it, said Karen McDonald, executive director of the service, which operates out of St. Michael’s Hospital.
The service identified it as N’-phenethyl-5-chloro nor-orphine or N’-phenethyl-6-chloro nor-orphine. The two compounds are so chemically similar that the lab cannot yet tell them apart. The same substance has also been detected in Vancouver, CP reported.
Orphines are a potent group of designer opioids that global drug monitors have been watching more closely. Late last year, the Toronto service began finding cychlorphine, an orphine-class opioid believed to be about 10 times stronger than fentanyl, in the city’s illicit supply.
The new find adds to a street supply that is already heavily mixed. In the service’s latest report, 96 per cent of samples sold as fentanyl in Toronto were cut with at least one non-opioid drug, usually a veterinary tranquillizer or a benzodiazepine. Eighty-three per cent contained more than one high-potency opioid, and more than a quarter contained all three: a high-potency opioid, a veterinary tranquillizer and a benzodiazepine.
Cristiana Stefan, a lab director and clinical biochemist at the Centre for Addiction and Mental Health, whose team analyzes the samples, told CP she is concerned about how the new opioid may interact with the other drugs in the mix. Her team spent weeks identifying the unknown substance.
Mixed-drug deaths have been climbing nationally. Public Health Agency of Canada data show the share of opioid or stimulant overdose deaths involving three or more substances rose to 42 per cent in 2023 from 20 per cent in 2018, or from 491 deaths to more than 1,500.
Dan Werb, a substance use epidemiologist at St. Michael’s Hospital, told CP that traffickers test higher-potency products and pull back when too many people die. He pointed to carfentanil, which the Public Health Agency of Canada says was involved in 20 per cent of apparent opioid overdose deaths at its peak in 2019 and three per cent in 2024. Werb said lower potency in the illicit supply has been a driving factor in the decline in overdose deaths in Canada since 2023, but warned that new products could reverse that at any time.
The find comes after other Canadian warnings about unusually potent street drugs this fall, including an RCMP warning in Salmon Arm, B.C., after a cluster of overdoses, and figures showing London-area opioid emergency visits had already passed all of 2025 by August. Naloxone, which can reverse an opioid overdose, is available free across the country; our guide lists where to get a free naloxone kit in every province. Toronto’s Drug Checking Service publishes its alerts and reports at drugchecking.community.
Via The Canadian Press.
If you find reporting like this useful, consider supporting Canada News Media, an independently owned Canadian newsroom.
Follow Canada News Media
Get the day's top Canadian stories and our two daily 60-second news videos wherever you scroll.
X Threads Facebook Instagram LinkedIn TikTok YouTube Pinterest Reddit Substack Flipboard Newsletter RSS













